Health experts of the country have pointed out that the benefits of the drug outweigh the potential risks it may have in the case of high-risk patients
Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Brii Bio announces amubarvimab/romlusevimab combination received approval from NMPA
The facility will supply clinical trial materials for the development of vaccines and biologics up to Phase II stage and is expected to be fully operational by early 2023.
TIB Molbiol excels in ultra-rapid assay development for emerging infectious diseases, strongly demonstrated during the Covid-19 pandemic
The country’s top heart transplant surgeon Dr. K.R Balakrishnan to be leading the programme for Jaslok
Vaccine effectiveness of complete vaccination against the moderate-to-severe disease was at 81 per cent
The multi-target agreement covers five programmes focused on off-the-shelf vaccines for cancer and infectious disease
This agreement marks a milestone for Baidu to use its strengths in computational biology to optimize mRNA vaccine and therapy designs
The partnership will help advance GreenLight's messenger RNA Covid-19 vaccine candidate
Subscribe To Our Newsletter & Stay Updated
